新型抗血小板和抗凝药物故意过量患者的出血风险评估
本研究为回顾性研究,分析4个州7个中毒控制中心10年间报告的322例阿哌沙班、氯吡格雷、噻氯匹定、达比加群、依度沙班、普拉格雷、利伐沙班和替格瑞洛急性过量病例。出血发生在16例(4.9%),其中氯吡格雷7例、利伐沙班6例、达比加群2例、阿哌沙班1例,大多数出血被分类为大出血(n=9)。与P2Y12受体抑制剂相比,新型抗凝药任何出血的相对风险为6.68(95%CI 2.63至17.1),大出血相对风险为18.1(95%CI 3.85至85.0)。结论认为新型抗凝药或抗血小板药急性过量与大出血风险小相关,但因子Xa抑制剂和直接凝血酶抑制剂的风险高于P2Y12受体拮抗剂。
要点
- 322例急性过量中,出血16例(4.9%),大出血9例。
- 出血病例分布:氯吡格雷7例、利伐沙班6例、达比加群2例、阿哌沙班1例。
- 新型抗凝药较P2Y12受体抑制剂任何出血相对风险6.68(95%CI 2.63至17.1)。
- 新型抗凝药较P2Y12受体抑制剂大出血相对风险18.1(95%CI 3.85至85.0)。
- 氯吡格雷占全部病例的260例(80.7%)。
适用人群与场景
- 4个州7个中毒控制中心10年间报告的急性过量摄入阿哌沙班、氯吡格雷、噻氯匹定、达比加群、依度沙班、普拉格雷、利伐沙班或替格瑞洛的患者。
研究设计与关键结果
- 研究类型为回顾性研究,共纳入322例急性过量病例,多数涉及氯吡格雷(260例,80.7%)。
- 出血发生在16例(4.9%),包括氯吡格雷7例、利伐沙班6例、达比加群2例、阿哌沙班1例;大多数出血为大出血(n=9)。
- 与P2Y12受体抑制剂相比,新型抗凝药任何出血的相对风险为6.68(95%CI 2.63至17.1)。
- 与P2Y12受体抑制剂相比,新型抗凝药大出血的相对风险为18.1(95%CI 3.85至85.0)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,新型抗凝药或抗血小板药急性过量与大出血风险小相关,但因子Xa抑制剂和直接凝血酶抑制剂的风险高于P2Y12受体拮抗剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: In recent years, the use of novel anticoagulants and antiplatelet agents has become widespread. Little is known about the toxicity and bleeding risk of these agents after acute overdose. The primary objective of this study is to evaluate the relative risk of all bleeding and major bleeding in patients with acute overdose of novel antiplatelet and anticoagulant medications.
METHODS: This study is a retrospective study of acute ingestion of apixaban, clopidogrel, ticlopidine, dabigatran, edoxaban, prasugrel, rivaroxaban, and ticagrelor reported to 7 poison control centers in 4 states during a 10-year span. The prevalence of bleeding for each agent was calculated, and hemorrhage was classified as trivial, minor, or major.
RESULTS: A total of 322 acute overdoses were identified, with the majority of cases involving clopidogrel (260; 80.7%). Hemorrhage occurred in 16 cases (4.9%), including 7 cases of clopidogrel, 6 cases of rivaroxaban, 2 cases of dabigatran, and 1 case of apixaban. Most cases of hemorrhage were classified as major (n=9). Comparing the novel anticoagulants with the P2Y12 receptor inhibitors, the relative risk for any bleeding with novel anticoagulant was 6.68 (95% confidence interval 2.63 to 17.1); the relative risk of major bleeding was 18.1 (95% confidence interval 3.85 to 85.0).
CONCLUSION: Acute overdose of novel anticoagulants or antiplatelet agents is associated with a small risk of significant hemorrhage. The risk is greater with the factor Xa inhibitors and direct thrombin inhibitors than with the P2Y12 receptor antagonists.
参考来源
- Levine M, Beuhler MC, Pizon A, et al. Assessing Bleeding Risk in Patients With Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications. Ann Emerg Med. 2017. PMID: 29032872. doi:10.1016/j.annemergmed.2017.08.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。